ArticleCancers2022

A Novel 2-Metagene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT.

Shivaprasad Patil et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.